Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
2021-002037-42Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SEA-CD40 in melanoma and solid tumor (2 arms), sponsored by Seagen Inc. Primary endpoint: Confirmed Objective Response Rate. Started Oct 2021; status: completed.
02
Drugs
SEA-CD40
03
Conditions
melanomasolid tumor
Beyond the preview
Go deeper on 2021-002037-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002037-42.